LIV-1 Antibody-Drug Conjugate: A Novel Therapeutic Agent for Breast Cancer

被引：0
|
作者：
Smith, L. M. [1 ]
Sussman, D. [1 ]
Nesterova, A. [1 ]
Westendorf, L. [1 ]
Duniho, S. [1 ]
Anderson, M. [1 ]
Mbow, B. [1 ]
Gregoire, A. [1 ]
Hunter, J. [1 ]
Whiting, N. [1 ]
Law, C. L. [1 ]
Benjamin, D. R. [1 ]
机构：
[1] Seattle Genet Inc, Bothell, WA USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P6-15-16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-15-16
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer
    Bosco, Emily E.
    Christie, Ronald J.
    Carrasco, Rosa
    Sabol, Darrin
    Zha, Jiping
    DaCosta, Karma
    Brown, Lee
    Phipps, Sandrina
    Du, Qun
    Bezabeh, Binyam
    Breen, Shannon
    Chen, Cui
    Reed, Molly
    Hinrichs, MaryJane
    Zhong, Haihong
    Xiao, Zhan
    Dixit, Rakesh
    Herbst, Ronald
    Tice, David A.
    CANCER RESEARCH, 2018, 78 (13)
  • [22] Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
    Burris, Howard A., III
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (06) : 807 - 819
  • [23] Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer
    Krop, Ian
    Winer, Eric P.
    CLINICAL CANCER RESEARCH, 2014, 20 (01) : 15 - 20
  • [24] CD70 antibody-drug conjugate: A novel therapeutic agent for platinum-resistant ovarian carcinoma
    Shiomi, Mayu
    Matsuzaki, Shinya
    Nakae, Ruriko
    Nakagawa, Satoshi
    Okazawa, Akiko
    Kobayashi, Eiji
    Ueda, Yutaka
    Serada, Satoshi
    Naka, Tetsuji
    Kimura, Tadashi
    CANCER RESEARCH, 2019, 79 (13)
  • [25] CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma
    Nakae, Ruriko
    Matsuzaki, Shinya
    Serada, Satoshi
    Matsuo, Koji
    Shiomi, Mayu
    Sato, Kazuaki
    Nagase, Yoshikazu
    Matsuzaki, Satoko
    Nakagawa, Satoshi
    Hiramatsu, Kosuke
    Okazawa, Akiko
    Kimura, Toshihiro
    Egawa-Takata, Tomomi
    Kobayashi, Eiji
    Ueda, Yutaka
    Yoshino, Kiyoshi
    Naka, Tetsuji
    Kimura, Tadashi
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 224 (02) : 197.e1 - 197.e23
  • [26] The evolving therapeutic landscape of antibody-drug conjugates in breast cancer
    Chen, Nan
    Michaels, Elena
    Howard, Frederick
    Nanda, Rita
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (12) : 1325 - 1331
  • [27] Novel targets for antibody-drug conjugate therapy
    Grandi, A. G.
    Campagnoli, S. C.
    Parri, M. P.
    De Camilli, E. D. C.
    Jin, B. J.
    Sarmientos, P. S.
    Grandi, G. G.
    Terracciano, L. T.
    Pileri, P. P.
    Viale, G. V.
    Grifantini, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 41 - 41
  • [28] Preclinical combinations of the antibody-drug conjugate SGN-LIV1A with chemotherapies show increased activity
    Li, Fu
    Anderson, Martha
    Hunter, Joshua
    Miyamoto, Jaime
    Ulrich, Michelle
    Kostic, Ana
    Law, Che-Leung
    Sussman, Django
    CANCER RESEARCH, 2016, 76
  • [29] Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer
    Li, Lan
    Cao, Jiawei
    Chen, Chunyan
    Qin, Yaqian
    He, Licai
    Gu, Haihua
    Wu, Guang
    HELIYON, 2023, 9 (04)
  • [30] The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer
    Taylor, Kathryn M.
    Morgan, Helen E.
    Smart, Kathryn
    Zahari, Normawati M.
    Pumford, Sara
    Ellis, Ian O.
    Robertson, John F. R.
    Nicholson, Robert I.
    MOLECULAR MEDICINE, 2007, 13 (7-8) : 396 - 406
12345